

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 30154

Title: A Comparative Study of Vonoprazan and Proton Pump Inhibitors in Helicobacter pylori Eradication Therapy

Reviewer's code: 00055108

Reviewer's country: Norway

Science editor: Yuan Qi

Date sent for review: 2016-09-15 22:01

Date reviewed: 2016-09-19 16:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

A Comparative Study of Vonoprazan and Proton Pump Inhibitors in Helicobacter pylori Eradication Therapy: Comments. 1. The study is well performed and nice reported. 2. It shows the efficacy problems regarding HPs regimes typical used the last decade. The regimes used in Japan somewhat differ from typical regimes used in Europe and US in dosage (PPIs/antibiotics) and duration. 3. I believe that it would have been of even greater interest to gain knowledge about Vonoprazan 20 mg twice daily regarding regimes used the last 5 years – because there are substantial differences regarding dosage/duration in the regimes reported used in this study (*older regimes*) compared to those used in clinical practices in the western world. This consideration should at least be discussed as a limitation regarding results and conclusion. 4. Yes the eradication rate is higher for Vonoprazan, but even that is lower than 90% which is not a satisfactory results regarding efficacy of HP eradication. Bear this in mind when reporting results. 5. CYP – polymorphism, what is the prevalence in the Japanese population, is it so large that it will explain results – or is it only a theoretical possibility? Elucidate on that matter – it would be of interest.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 30154

Title: A Comparative Study of Vonoprazan and Proton Pump Inhibitors in Helicobacter pylori Eradication Therapy

Reviewer's code: 00044980

Reviewer's country: Japan

Science editor: Yuan Qi

Date sent for review: 2016-09-15 22:01

Date reviewed: 2016-09-27 19:48

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript is the retrospective study of Helicobacter pylori eradication using vonoprazan and conventional PPIs. I have several comments as follows. 1. Were there any patients who were excluded by adverse events? Authors should mention the data of both Intention to treat analysis and Per protocol analysis in the first-line treatment and the second-line treatment. 2. Authors should mention the clinical characteristics of patients in VPZ group and PPIs group. 3. Authors should mention the number of patients who underwent the second-line treatment. 4. Authors mention that smoking habit alone showed a significant difference among the four groups. Authors should mention the multivariable analysis of smoking habit.